CDY potential, page-63

Hi Trae. I think you were just trying to say that CDY will benefit significantly from a repricing of the sector. This is what the analysts keep saying .

Why is CDY mispriced? It's not just that sector is illiquid. In simple terms ,companies that are now earning at least some revenue in the clinic, the pharmacy or in OTC sales are perceived as being as risky as those that do not. As Baillieu Holst point out , the Australian market (in comparison to the US) is unable to understand basic science. The difference between a blockbuster and an antibody is for example completely lost on the locals as is an ability to grade the probability of success for any pipeline. The locals may never understand the value of a new and distinct oncology target until tumor shrinkage is reported in the Daily Telegraph.... then they will want to pile in. What the local punters will recognise is a reasonable income statement and balance sheet.

As posted CDY is not risk free. Delays can and probably will happen ..... thought the run we have had lately is a bit like a dream. However the company has so many iron in the fire there will always be a net advancement on good news somewhere in these pipelines. The diversification level in this company is as good if not better than most mid caps.

cheers